ReviewMolecular biology reports2022
Corticosteroids for COVID-19: worth it or not?
Review in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis.World journal of hepatology · 2026Article
- Occurrence of antibacterials, antivirals, and anti-inflammatory pharmaceuticals for COVID-19 treatment as emerging contaminants in the Chinese freshwater environment before, during and after the pandemic: the need for dynamic eco-pharmacovigilance.Environmental health and preventive medicine · 2026Review
- Optimization, Characterization and Pharmacological Validation of the Endotoxin-Induced Acute Pneumonitis Mouse Model.Biomedicines · 2025Article
- A meta-analysis of the efficacy and safety of immunomodulators in the treatment of severe COVID-19.The Journal of international medical research · 2025Article
- Infection to hypertension: a review of post-COVID-19 new-onset hypertension prevalence and potential underlying mechanisms.Frontiers in cardiovascular medicine · 2025Review
- A brief overview of SARS-CoV-2 infection and its management strategies: a recent update.Molecular and cellular biochemistry · 2024Review
- Article
- COVID-19 in Bangladesh: Wave-centric assessments and mitigation measures for future pandemics.Heliyon · 2023Review
- Secondary pulmonary infection byWorld journal of clinical cases · 2023Article
- IL-6 and cfDNA monitoring throughout COVID-19 hospitalization are accurate markers of its outcomes.Respiratory research · 2023Article
- Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023Review
- Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill.International journal of molecular sciences · 2023Article
- Effect of 2 Different High-Dose Methylprednisolone Treatments on Clinical Outcomes in Severe COVID-19 Patients.Thoracic research and practice · 2023Article
- Glucocorticoid Therapy in COVID-19.Seminars in respiratory and critical care medicine · 2023Review
- Drugs for COVID-19: An Update.Molecules (Basel, Switzerland) · 2022Review
- Glucocorticoids and COVID-19.Pharmacological research · 2022Review
- Management of hyperinflammation in COVID-19 patients.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Neddylation tunes peripheral blood mononuclear cells immune response in COVID-19 patients.Cell death discovery · 2022Article
- Corticosteroid Therapy in COVID-19 Associated With In-hospital Mortality in Geriatric Patients: A Propensity Matched Cohort Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges.Beni-Suef University journal of basic and applied sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced COVID-19 implied the presence of excessive proinflammatory cytokines and chemokines in patients causing significant morbidity and mortality. To diminish systemic hyper inflammation, a few physicians and researchers have utilized corticosteroids. Corticosteroid implementation has increased after the publication of interim guidelines regarding corticosteroid use in COVID-19 patients by WHO, despite the remaining controversies regarding long-term side effects and disease progression capability of corticosteroids. In different studies, the implementation of corticosteroids on COVID-19 patients revealed controversial results, which require further intensive research. This review will present the current outcomes and possibilities of using corticosteroids to treat COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.